ArticleDiagnostic cytopathology2026
AUS in Thyroid Cytology: A 21-Year Institutional Experience and the Impact of Atypia Subclassification.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Atypia of Undetermined Significance (AUS) category remains one of the most controversial groups in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). We aimed to assess AUS outcomes at our institution over a 21-year period.
methodsThyroid fine needle aspiration (FNA) cases between 2000 and 2021 were retrospectively reviewed, and AUS diagnoses were identified. Cases were subclassified as nuclear (AUS-N) or other atypia (AUS-O). The AUS rates per year and cytopathologist, risk of malignancy (ROM), and radiological features were analyzed.
resultsThere were 15,099 thyroid FNAs, of which 553 initial AUS cases were included. The AUS rate was 0.7% and 6.6% before and after the implementation of the TBSRTC. AUS rates among cytopathologists ranged from 2.8% to 8.8%. Of the 553 cases, 168 (30%) underwent surgery, 269 (48.6%) had a repeat FNA, and 116 (20.9%) were observed or lost to follow-up. Pre-TBSRTC the overall ROM was 20%, and post-TBSRTC 30.1% and 26.7% when NIFTP was considered malignant, and nonmalignant, respectively. ROM was significantly higher in AUS-N than AUS-O (39% vs. 20.7% with NIFTP malignant; 36% vs. 17.6% without; p < 0.01). ROM did not differ significantly between patients with one or two consecutive AUS diagnoses (26.7% vs. 25%). On ultrasonographic findings, calcifications, and cystic changes were more frequent in AUS-N, while nodule size and multiplicity were similar between groups.
conclusionIn conclusion, AUS-N and AUS-O demonstrated significantly different ROMs, supporting the 2023 TBSRTC subclassification. Repeat FNA led to diagnostic reclassification in a substantial proportion of cases, supporting its role as an acceptable management strategy, particularly in settings with limited access to molecular testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.